Chemocentryx, Inc.

J J Wright

Penglie Zhang

Subhabrata Bapi Sen

James Bradley Aggen

Thomas J Schall

Solomon Ungashe

Zheng Wei

Brian E McMaster

Andrew Pennell

Daniel J Dairaghi

Mark Penfold

Anita Melikian

Jennifer M Burns

Brett Permack

Anita Melikan

Wei Chen

Andrew M Pennell

Brian E Mcmaster

Daniel Joseph Dairaghi

Subhabrata Sen

Valeri V Martichonock

M K Andrew Pennell

Compounds are provided that act as potent antagonists of the CCR9 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.

Aryl sulfonamides

Pharmaceutical compositions containing organic compounds or salts thereof that serve as modulators for the SDF-1 or I-TAC chemokines are disclosed. The compounds and compositions are useful in the treatment of cancer, especially in the inhibition of cancer proliferation, growth, and metastasis. Methods of interfering with SDF-1 and/or I-TAC binding to the CCXCKR2 receptor and treating cancer using the compounds and pharmaceutical compositions of the present invention are also disclosed.

Inhibitors of human tumor-expressed CCXCKR2

Compounds are provided that act as potent antagonists of chemokine receptors. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of chemokine receptor-mediated diseases, and as controls in assays for the identification of chemokine antagonists.

Bis-aryl sulfonamides

Methods for treating CMV or a CMV-related disease are provided that use compounds having the formula: wherein Ar is a substituted or unsubstituted 5&#x2013;14 membered heteroaryl group having from 1 to 5 heteroatoms as ring members; Ris selected from the group consisting of substituted or unsubstituted aryl(C&#x2013;C)alkyl, heteroaryl(C&#x2013;C)alkyl, &#x2014;C(O)R, and &#x2014;C(O)NRR, wherein each Rand Rindependently is substituted or unsubstituted aryl, substituted or unsubstituted aryl(C&#x2013;C)alkyl, substituted or unsubstituted (C&#x2013;C)cycloalkyl(C&#x2013;C)alkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroaryl(C&#x2013;C)alkyl and substituted or unsubstituted hetero(C&#x2013;C)cycloalkyl(C&#x2013;C)alkyl; Ris H or (C&#x2013;C)alkyl; and Zis a substituted or unsubstituted hetero(C&#x2013;C)bicycloalkyl group.

Bicyclic compounds as inhibitors of chemokine binding to US28

Arylamines as inhibitors of chemokine binding to US28

Growing community of inventors

Redwood City, CA, United States of America

J J Wright